Logo von

News and Events

EUCODIS‘ scientists contribute to new findings on structural and functional variations on chitin-binding domains of a lytic polysaccharide monooxygenase

Chitin is one of the most common structure giving polysaccharides and can be naturally found in e.g. fungi and arthropods. It is used to produce the commercially interesting chitosan, which has increasing applications in industries like pharma, agriculture and food, textile and cosmetics. The degradation of chitin to chitosan is carried out by deacetylation, either using alkaline or in a more environmentally friendly manner via biocatalysts.

 

Among others, the lytic polysaccharide…

More Information

FuturEnzymes: Enzyme innovation EU project for eco-friendly consumer product development

EUCODIS Bioscience will develop new microbial enzymes for generating ecofriendly and innovative consumer products like detergents, textiles and cosmetics together with partners of the FuturEnzyme consortium. FuturEnzyme has received a total funding of about six million Euros from the Horizon 2020 framework program, that has started in June 2021.   

 

Consumer products like textiles, detergents and cosmetics can harm the environment by discharging chemical products into the environment during…

More Information

EUCODIS expands its Candida antarctica lipase panel

Based on the overwhelming success of Candida antarctica lipase B (CalB) variants introduced in 2017, EUCODIS Bioscience has now expanded its CalB collection with novel immobilized variants.

 

Lipases belong to the family of esterases and naturally convert triglycerides and fats into fatty acids and glycerol in aqueous conditions. The opposite reaction is catalyzed if water is absent and, consequently, lipases can be used as versatile tools in hydrolytic, esterification and transesterification…

More Information

EUCODIS enzymes now also to purchase from Biosynth Carbosynth

EUCODIS Bioscience and Biosynth Carbosynth, a global supplier of biochemicals and custom chemical synthesis services, have agreed upon a new distribution agreement for EUCODIS enzyme products. We are looking forward to leveraging our business activities by directly reaching out to the wide network of Biosynth Carbosynth customers via its online catalogue portal.

 

Biosynth Carbosynth now offers over 70 products for industrial biocatalysis including lipases, peroxidases, nitrilhydratases,…

More Information

SARS-CoV-2 Main Protease now available at EUCODIS

We are proud to announce the addition of the SARS-CoV-2 main protease (SARS-CoV-2 Mpro) to our product portfolio. The SARS-CoV-2 Mpro enzyme was collaboratively developed by experts of EUCODIS and Biosynth Carbosynth for research purposes in Covid-19 diagnostics, drug development and for in vitro research on viral replication.

 

SARS-CoV-2 Mpro is a key enzyme for the successful replication and transcription of SARS-CoV-2 by digesting replicase polyproteins at conserved cleavage sites resulting…

More Information

EUCODIS and the Norwegian University of Life Science identified a tri-modular bacterial enzyme efficiently degrading chitin

Scientists of EUCODIS Bioscience and the Norwegian University of Life Science teamed up for enzyme identification and production within the scope of the ChitoTex Project (lead: Fraunhofer Institute, Stuttgart). This project is aiming to establish an environmentally friendly process for the utilization of a waste stream (insect chitin) for novel applications like chitosan in the textile industry.

 

Chitosan is a polysaccharide that can be used as sizing agent in the textile industry for…

More Information

Development of rapid novel SARS-CoV-2 diagnostics started

Enzyme specialists from EUCODIS Bioscience and diagnostics experts from Biosynth-Carbosynth have teamed up to develop a novel diagnostic tool for the fast and reliable detection of an acute SARS-CoV-2 infection.

 

Based on viral enzymatic activities and a novel enzymatic bioluminescence substrate, the diagnostic test should identify active as well as asymptomatic early infections within minutes – which would be a tremendous help in the fight against the SARS-CoV-2 pandemic.

 

In an acute…

More Information

Note on COVID-19: Operations without major disruptions at EUCODIS

With regard to the current situation concerning COVID-19 in Austria Eucodis reacted promptly and implemented preventive measures to minimize the impact of COVID-19-related disruptions on our business. We are currently running our operations without major disruptions and are striving to continue to do so.

 

We are monitoring the COVID-19 situation and adapt our lean organization continuously to make sure development timelines are being met and products will be delivered on time. We will provide…

More Information

Scientists from EUCODIS contributed to research published in Nature Catalysis

Improving biocatalytical processes through genetically engineering proteins is one great challenge in today’s biotechnological industry. One new approach regarding this is engineering multiple active sites - both from biological and abiological origin - into one protein. A team around Manuel Ferrer from the Institute of Catalysis in Madrid, Spain together with two members from the research department of EUCODIS have mastered this challenge and could publish their results in the current issue of…

More Information

Novel Catalase for complete neutralization of hydrogen peroxide in agar plates

EUCODIS Bioscience, an established Austrian enzyme engineering and manufacturing company, developed and patented a catalase as a novel neutralizer in environmental monitoring media and offers either a collaboration or OEM supply of the enzyme or the technology itself for licensing.

EUCODIS Bioscience’s patented recombinant catalase formulation is unique as it is the only one worldwide that can be applied to agar plates due to its increased stability at high temperatures (stable at 55°C during…

More Information

ChitoTex and Eucodis Bioscience: Enzyme development for chitosan production

Within the ChitoTex project EUCODIS Bioscience, the Fraunhofer IGB, the Norwegian University of Life Sciences (NMBU) and others collaborated to establish a new enzyme based approach to produce chitosan for the treatment of textile fibers and yarns in a more sustainable way. EUCODIS played an important role in the screening and modification of those enzymes aiming to develop suitable expression systems as well as efficient, stable, recombinant enzymes to produce chitosan.

The Fraunhofer IGB laid…

More Information

EUCODIS Bioscience developed enzyme and enzymatic production method for PrEP Biopharm drug intermediate

EUCODIS Bioscience, an Austrian biotechnology company with strong expertise in industrial enzyme development, announces the completion of a development project for PrEP Biopharm Limited. In this collaboration, EUCODIS Bioscience developed an enzymatic method for production of a drug intermediate of PrEP-001, an immunomodulator for the prevention of the common cold and influenza and supplied key consumables for the GMP manufacturing process.

PrEP Biopharm Limited is a U.K.-based clinical stage,…

More Information

Eucodis starts commercialization of tubulysin A and B

Eucodis Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and Eucodis now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.

Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production…

More Information

Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

An anti-Her2 antibody conjugated to the maytansinoid DM1 using the novel CTATTM-linker technology (“CTAT-ADC”) was tested in nude mice with SKOV-3 cancer cell xenografts for maximum tolerated dose (“MTD”) and…

More Information

UPCOMING EVENTS

EFIB 2021

06 - 07 October 2021
Vienna

Bio-Europe 2021

25 - 28 October 2021
Online

CPhI worldwide 2021

09 - 11 November 2021
Milan